CT
KRYS icon

Caldwell Trust’s Krystal Biotech KRYS Stock Holding History

Caldwell Trust’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.9K Hold
250
– – 0.01% 421
2026
Q1 		$64.6K Hold
250
– – 0.01% 459
2025
Q4 		$61.6K Hold
250
– – 0.01% 454
2025
Q3 		$44.1K Hold
250
– – ﹤0.01% 495
2025
Q2 		$34.4K Hold
250
– – ﹤0.01% 504
2025
Q1 		$45.1K Hold
250
– – ﹤0.01% 472
2024
Q4 		$39.2K Hold
250
– – ﹤0.01% 479
2024
Q3 		$45.5K Hold
250
– – ﹤0.01% 467
2024
Q2 		$45.9K Buy
+250
New +$42K 0.01% 464

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Caldwell Trust's KRYS Position: Q2 2026 in Review

Caldwell Trust held its Krystal Biotech (KRYS) position steady in Q2 2026 at 250 shares worth $92.9K. The position accounts for 0.01% of the portfolio, ranked #421.

Caldwell Trust first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Caldwell Trust held 250 shares of Krystal Biotech worth $92.9K as of Q2 2026.
  • Caldwell Trust left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up 0.01% of Caldwell Trust's portfolio in Q2 2026, its #421 holding.
  • Caldwell Trust first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Caldwell Trust's 13F filing for Q2 2026, filed 3 Aug 2026.